The Insight Partners published latest research study on “Overactive Bladder Treatment Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028 – COVID-19 Impact and Global Analysis – by Pharmacotherapy, Disease Type, and Geography,” the global overactive bladder treatment market size was valued at USD 4,295.93 million in 2021 and is projected to reach USD 5,333.92 million by 2028; it is estimated to grow at a CAGR of 3.1% from 2022 to 2028.
Global Overactive Bladder Treatment Market: Competitive Landscape and Key Developments
Key players operating in the overactive bladder treatment market include Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Pfizer Inc.; AbbVie Inc; Teva Pharmaceutical Industries Ltd; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc; Medtronic Plc; Allergan; and Colorado Urology Associates, PLLC. These players are focusing on expanding, diversifying their market presence, and acquiring a novel customer base, thereby tapping into prevailing business opportunities.
In February 2022, Alembic Pharmaceuticals received approval from the US health regulator for its generic version of fesoterodine fumarate extended-release tablets, used for overactive bladder in adults with symptoms of urinary incontinence, urgency, and frequency. The US Food & Drug Administration (USFDA) approved strengths of 4 mg and 8 mg of fesoterodine fumarate extended-release tablets for the Abbreviated New Drug Application (ANDA).
In February 2022, AbbVie announced that the US Food and Drug Administration (FDA) had approved BOTOX for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
In April 2021, Medtronic plc announced approval from the US Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally developed implantable tibial neuromodulation (TNM) device—a therapy designed to provide relief from symptoms of bladder incontinence.
In July 2020, Hisamitsu Pharmaceutical Co., Inc. announced the approval of manufacturing and marketing for OABLOK PATCH in Thailand. The product is a systemic transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology for treating overactive bladder with symptoms such as urinary urgency and frequent urination.
Source: Finance.Yahoo